https://www.selleckchem.com/pr....oducts/mevastatin.ht
potentially improve coverage of comorbidity.Progesterone receptors (PRs) ligands are being tested in luminal breast cancer. There are mainly two PR isoforms, PRA and PRB, and their ratio (PRA/PR may be predictive of antiprogestin response. Our aim was to investigate the impact of the PR isoform ratio on metastatic behaviour, the PR isoform ratio in paired primary tumours and lymph node metastases (LNM) and, the effect of antiprogestin/progestins on metastatic growth. Using murine and human metastatic models, we demonstrated that tu